![]() | ![]() |
Formats:
|
||||||||||||||||||
Copyright © 2003, American Society for Microbiology Members of the AP-1 Family, c-Jun and c-Fos, Functionally Interact with JC Virus Early Regulatory Protein Large T Antigen Laboratory of Molecular Neurovirology, Center for Neurovirology and Cancer Biology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122,1 Laboratory of Biology, Don C. Gnocchi Foundation, IRCCS, 20148, Milan, Italy2 *Corresponding author. Mailing address: Laboratory of Molecular Neurovirology, Center for Neurovirology and Cancer Biology, College of Science and Technology, 015-96, Room 203, 1900 North 12th St., Philadelphia, PA 19122. Phone: (215) 204-0636. Fax: (215) 204-0679. E-mail: msafak/at/temple.edu. Received November 13, 2002; Accepted January 28, 2003. This article has been cited by other articles in PMC.Abstract The activating protein 1 (AP-1) family of regulatory proteins is characterized as immediate-early inducible transcription factors which were shown to be activated by a variety of stress-related stimuli and to be involved in numerous biological processes, including cellular and viral gene expression, cell proliferation, differentiation, and tumorigenesis. We have recently demonstrated the involvement of the AP-1 family members c-Jun and c-Fos in transcriptional regulation of the human polyomavirus, JC virus (JCV), genome. Here, we further examined their role in JCV gene regulation and replication through their physical and functional interaction with JCV early regulatory protein large T antigen (T-Ag). Transfection and replication studies indicated that c-Jun and c-Fos can significantly diminish T-Ag-mediated JCV gene transcription and replication. Affinity chromatography and coimmunoprecipitation assays demonstrated that c-Jun and T-Ag physically interact with each other. Results from band shift assays showed that the binding efficiency of c-Jun to the AP-1 site was reduced in the presence of T-Ag. In addition, we have mapped, through the use of a series of deletion mutants, the regions of these proteins which are important for their interaction. While the c-Jun interaction domain of T-Ag is localized to the middle portion of the protein, the T-Ag interacting domain of c-Jun maps to its basic-DNA binding region. Results of transient-transfection assays with various c-Jun mutants and T-Ag expression constructs further confirm the specificity of the functional interaction between c-Jun and T-Ag. Taken together, these data demonstrate that immediate-early inducible transcription factors c-Jun and c-Fos physically and functionally interact with JCV major early regulatory protein large T-Ag and that this interaction modulates JCV transcription and replication in glial cells. The activating protein 1 (AP-1) family of transcription factors was shown to be involved in a wide variety of cellular processes, including cell proliferation, cellular and viral gene expression, cell death, survival, and differentiation, and tumorigenesis (52). In particular, c-jun knockout studies resulted in an embryonically lethal phenotype. Furthermore, mouse embryonic fibroblasts established from the c-Jun knockout mouse showed severe proliferative defects and can be propagated only once or twice before entering a premature senescence (23). Biochemical purification showed that AP-1 is not a single transcription factor but instead is a series of related dimeric complexes of the Jun (c-Jun, JunB, and JunD) and Fos (c-Fos, FosB, Fra-1, and Fra-2) families (4, 62). Each family member is a phospho-nuclear protein and composed of three distinct functional domains, including a carboxy-terminal leucine-zipper domain followed by an adjacent basic DNA binding domain and an amino-terminal transactivation domain. The family members form homo- and heterodimers within the family and outside the family with those factors that contain basic-leucine zipper (bZIP) motifs, such as the CREB and ATF2 families (50). Dimerization occurs through leucine repeats that are clustered proximally to the carboxy-terminal region. It is interesting that unlike c-Jun family members, the Fos family members form only heterodimers. DNA binding activity of AP-1 is mediated by the basic DNA binding domain and occurs in a hierarchical manner. Following dimerization, the specific residues in the basic region (62) make base contacts with target sequences on DNA, which are known as the 12-O-tetradecanoyl-13-phorbol acetate-response element (TGACTCA, TRE). These sequences are present within the promoter regions of many inducible genes (3, 58). Transcriptional activity of this family of factors is regulated by the N-terminal transactivation domain, largely in a phosphorylation-dependent manner. For example, phosphorylation of serine63 and serine73 residues of c-Jun by the Jun N-terminal kinase (JNK) family of kinases results in a large increase in its ability to interact with the CBP/p300 family of cofactors and, to a similar extent, in the transcriptional activation potential of the protein (4, 62). AP-1 family members are induced by a wide variety of signals, including, but not limited to, UV light, ionizing radiation, oxidative stress, neuronal depolarization, cytokines (tumor necrosis factor α, gamma interferon, and interleukin-1), and viral infection (9, 13, 17, 18, 21, 50, 51, 63). They are collectively known as proto-oncogenes because of their high sequence homology to some retroviral encoded oncogenic proteins and their involvement in many cellular processes, including cell proliferation, survival, and apoptosis (8, 30, 50, 56, 62). JC virus (JCV) is a human polyomavirus with a double-stranded covalently linked circular genome and is the etiological agent of a fatal demyelinating disease, progressive multifocal leukoencephalopathy (PML), in immunocompromised individuals (6). JCV lytically infects oligodendrocytes, the myelin-producing cells of the central nervous system, and utilizes a clathrin-mediated pathway to enter the cells (31, 36, 61). The viral genome is composed of regulatory and coding regions. The regulatory region contains DNA target sequences for both viral and cellular transcription factors, including NF-κB (39, 45), Tst-1 (41, 60), NF-1 (1, 2, 35), Sp-1 (20), GBP-i (38), YB-1 (24, 44, 46, 48), and Purα (11, 46). The viral coding regions encode early regulatory proteins (small t, large T, and isoforms of early proteins, T′) and late structural capsid proteins (VP-1, VP-2, and VP-3). In addition to structural proteins, the leader sequences of late transcripts also encode a basic regulatory protein, Agnoprotein, which has been recently shown to play a role in viral DNA replication and transcription (43, 48). Although little is known about the function of small t antigen, the large T antigen (T-Ag) was shown to be a multifunctional phosphoprotein involved in both viral DNA replication (32-34, 54) and viral gene transcription (25, 29). Additionally, T-Ag is oncogenic; its expression can lead to the induction of tumors of neuronal origin in experimental animals (27, 53, 57), and its genome has been detected in several human tumors (26, 28, 40). In addition, the several spliced variants of early proteins were shown to differentially interact with the retinoblastoma family of tumor suppressor proteins (14, 55). JCV exhibits significant sequence homology (70%) to its counterpart simian virus 40 (SV40) in coding regions (15), and the early gene product, large T-Ag, for each virus displays similar functions in viral DNA replication and transcription. Previous studies indicated that SV40 large T-Ag cooperates with c-Jun in down-regulation of myelin Po gene expression in secondary Schwann cells (7). It was also demonstrated that cells undergo apoptosis when SV40 T-Ag and c-Jun coexpressed in HaCat cells (12). In addition, we and other investigators demonstrated that c-Jun interacts with its target DNA sequences present within the control region of JCV and positively regulates viral gene transcription (2, 42). Altogether, these studies suggested the possibility of a functional interaction between T-Ag and AP-1 family members such as c-Jun and perhaps with other family members as well. In this report, we used JCV as a model system and investigated the effect of AP-1 family members c-Jun and c-Fos on JCV T-Ag-mediated functions and provide experimental evidence that AP-1 family members physically and functionally interact with JCV large T-Ag and negatively affect both T-Ag-dependent viral gene transcription and replication. MATERIALS AND METHODS Cell lines. U-87MG (ATCC HTB14), a human glioblastoma cell line, was grown in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum and antibiotics (penicillin-streptomycin, 100 μg/ml) and was maintained at 37°C in a humidified atmosphere with 7% CO2. HJC-15b cells (37) derived from hamster brain tumors (59) which were induced by JCV were grown in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum and antibiotics (penicillin-streptomycin, 100 μg/ml). Plasmid constructs. The pBLCAT3-Mad-1L reporter construct containing the regulatory region of JCV Mad-1 strain in the late orientation has been previously described (11). Expression plasmids for RSV-c-Jun and RSV-c-Fos were kindly provided by B. E. Sawaya (Temple University). pGEX2T-T-Ag (1-688) and its deletion mutants, pGEX2T-T-Ag (1-411), pGEX2T-T-Ag (1-265), pGEX2T-T-Ag (1-81), pGEX2T-T-Ag (266-688), pGEX2T-T-Ag (412-688), and pGEX2T-T-Ag (629-688), were previously described (44). pGEX2T-c-Jun (1-333) and its deletion mutants, pGEX2T-c-Jun (1-257), pGEX2T-c-Jun (1-150), pGEX2T-c-Jun (1-151-333), pGEX2T-c-Jun (258-333), and pGEX2T-c-Jun (281-333), were created by PCR amplification utilizing the following specific primers. The forward primers were c-Jun 5′ (5′-ATGACTGCAAAGATGGAAACGACCTTC-3′), FP aa 258 (5′-AAGCGCATGAGGAACCGCATC-3′), FF aa 151 (5′-ACTGCAAAGATGGAAACGACCTTC-3′), and FF aa 281 (5′-GAGGAAAAAGTGAAAACCTTG-3′). The reverse primers were c-Jun-3′ (5′-TCAAAATGTTTGCAACTGCTG-3′), RP aa 280 (5′TCACAGCCGGGCGATTCTCTCCAG-3′), RP aa 257 (5′-TCACCATGTCAGTGGGGGACAGGG-3′), and RP aa 150 (5′-TCACACCGAGGGTACCGCGGGAGC-3′). RSV-c-Jun plasmid was used as a template in PCR amplification. pGEX2T-c-Fos was created by PCR amplification utilizing 5′ primer (5′-ATGTTCTGCGGCTTCAACGCAGACTAC-3′) and 3′ primer (5′-TCACAGGGCCAGCAGCGTGGGTGAGCT-3′) by subcloning the PCR product into BamHI/EcoRI sites of pGEX2T vector. RT-PCR-amplified human c-Fos cDNA was used as a template in PCR. pcDNA3-HA-c-Jun (1-257) and pcDNA3-HA-c-Jun (258-333) expression plasmids were also created by PCR amplification. Corresponding regions were PCR amplified and subcloned into BamHI/EcoRI sites of pcDNA3 and tagged with hemagglutinin tag in-frame at the 5′-end. CMV-T-Ag expression plasmid has been previously described (10). Reporter gene assays. A reporter construct containing the JCV regulatory region in late (pBLCAT3-Mad-1L) orientation was transiently transfected into U-87MG cells by the calcium-phosphate precipitation method (19) either alone or in combination with c-Jun (RSV-c-Jun) and c-Fos (RSV-c-Fos) and JCV T-Ag (CMV-T-Ag) expression plasmids. Plasmid concentrations used in each transfection experiment are indicated in the text and/or in the respective figure legends. The total amount of DNA transfected into the cells was normalized by using respective empty vectors. A glycerol shock was applied at 3 h posttransfection, and the medium was replenished. At 48 h posttransfection, cells were lysed by freeze-thaw cycles. After clearance of cell debris, the protein concentration of the supernatants was normalized, and CAT (chloramphenicol acetyltransferase) activity of samples was determined with 100 μg of protein for each sample. Transfections were repeated more than three times with different plasmid preparations. Standard deviations are indicated by error bars. Replication assay. Replication assays were carried out as previously described (47). Briefly, a replication-competent plasmid, pBLCAT3-Mad-1L, containing the regulatory region of Mad-1 strain of JCV was transfected alone or in combination with expression vectors CMV-T-Ag, RSV-c-Jun, RSV-c-Fos, CMV-c-Jun (1-257), and CMV-HA-c-Jun (258-333) into U-87MG cells (0.4 × 106 cells per 60-mm-diameter plate) with the calcium phosphate precipitation method. Plasmid concentrations used in transfections are indicated in respective figure legends, and the total amount of DNA transfected into the cells was normalized with appropriate empty vectors. A glycerol shock was applied at 4 h posttransfection, and the medium was replenished. At 72 h posttransfection, low-molecular-weight DNA containing both input and replicated plasmids was isolated by the Hirt method (22), digested with BamHI and DpnI enzymes, resolved on 1% agarose gel, and analyzed by Southern blotting. The bands corresponding to the replicated DNA were quantitated by utilizing a densitometer (Bio-Rad Fx PhosphorImager) with Quantity One Software. The degree of inhibition of T-Ag-mediated JCV DNA replication by AP-1 was expressed as percent inhibition with respect to the degree of viral DNA replication in the presence of T-Ag alone. Nuclear extract preparation. Nuclear extracts from U-87MG (treated or untreated with UV) was prepared by a modification of the miniextract protocol, as described by Schreiber et al. (49). UV-treated and untreated cells were harvested by trypsinization, washed once with complete Dulbecco's modified Eagle medium and twice with phosphate-buffered saline (PBS), and transferred to an Eppendorf tube. The cells were then resuspended in cold hypotonic buffer [10 mM N-2-hydroxyethylpipezine-N-2-ethanesulfonic acid (HEPES) (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM ethylene glycol bis(β-aminoethyl ether)-N,N,N′,N,-tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF)] and allowed to swell on ice. Cellular membranes were cleared by the addition of Nonidet P-40 (0.5% final concentration) and vortexing. The nuclei were pelleted by centrifugation at 10,000 × g, resuspended in cold extraction buffer (containing 20 mM HEPES [pH 7.9], 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, and 1 mM DTT and supplemented with a cocktail of protease inhibitors), and extracted at 4°C for 15 min on a racking platform. The nuclear extract was centrifuged, and the supernatant was frozen at −70°C. Mobility band shift assay. Band shift assays were carried out as described previously (46). Briefly, a double-stranded synthetic oligonucleotide containing JCV AP-1 binding site (5′-CAAGCATGAGCTCATACCTA-3′) was end labeled with [γ-32P]ATP with T4 polynucleotide kinase and gel purified. Nuclear extracts (10 μg/lane) prepared from U-87MG cells, untransfected or transfected with a JCV large T-Ag expression plasmid (CMV-T-Ag), were incubated with labeled probe (40,000 cpm/lane) in a binding buffer containing 1.0 μg of poly(dI-dC), 12 mM HEPES (pH 7.9), 4 mM Tris (pH 7.5), 60 mM KCl, 5 mM MgCl2, and 1.0 mM DTT. The reaction mixture was incubated at 4°C for 30 min to allow assembly of DNA-protein complexes. Experimental conditions for competitive band shift and antibody supershift assays are described under respective figure legends. The complexes were resolved on a 6% polyacrylamide gel in 0.5× TBE (1× TBE is 89 mM Tris-HCl [pH 8.0], 89 mM boric acid, and 2 mM EDTA [pH 8.0]). Gels were dried, and complexes were detected by autoradiography. UV treatment. U-87MG cells were plated on 100-mm-diameter tissue culture dishes and grown to subconfluence. Cells were then washed twice with PBS and kept under a thin layer of PBS until treated with UV (254 nm, 40 J/m2). Cells were subsequently incubated in fresh media and harvested 16 h posttreatment for nuclear extract preparation. In vitro transcription-translation assay. Full-length c-Jun was radiolabeled with [35S]methionine by using a TNT coupled in vitro transcription-translation system (Promega, Madison, Wis.) in accordance with the recommendations of the manufacturer. Coimmunoprecipitation and Western blot analysis. Two micrograms of anti-c-Jun antibody (KM-1; Santa Cruz) or preimmune serum was incubated with 0.5 mg of nuclear extract prepared from U-87MG cells overnight at 4°C with continuous rocking. Immunocomplexes were precipitated with the addition of protein A-Sepharose beads (20 μl of 50% slurry) (Pharmacia, Piscataway, N.J.) for an additional 2 h and washed extensively with lysis buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% NP-40, and a cocktail of protease inhibitors. Immunocomplexes were then resolved by sodium dodecyl sulfate (SDS)-10% polyacrylamide gel electrophoresis (PAGE) and transferred onto an immunoblotting membrane. The blots were then probed with an anti-SV40 T-Ag antibody (Ab-2 416) which cross-reacts with JCV T-Ag, developed with an ECL detection kit (Amersham-Pharmacia, Piscataway, N.J.) in accordance with the manufacturer's recommendations, and analyzed for the presence of T-Ag. GST affinity chromatography assays (GST pull-down). All glutathione S-transferase (GST) and GST fusion proteins were expressed and purified as described previously (48). For GST pull-down assays, 2 μg of either GST alone or GST-c-Jun or the deletion mutants of c-Jun immobilized on glutathione-Sepharose beads were incubated with 0.2 mg of nuclear extract prepared from U-87MG cells treated with UV overnight at 4°C in lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.5% Nonidet P-40 supplemented with a cocktail of protease inhibitors (Sigma). Formed complexes were washed extensively with lysis buffer and resolved by SDS-10% PAGE followed by Western blot analysis with anti-Jun antibody (KM-1; Santa Cruz). Alternatively, 4 μl of 35S-labeled in vitro-translated full-length c-Jun was incubated with GST alone or full-length GST-c-Jun fusion protein immobilized on glutathione-Sepharose beads. All reactions were performed in 400 μl of total reaction volume in lysis buffer overnight at 4°C with continuous rocking. After incubation, the beads were washed extensively with lysis buffer, and complexes were resolved by SDS-10% PAGE. Gels were dried and analyzed for c-Jun by autoradiography. Similarly, GST pull-down assays were also performed for GST-c-Fos fusion protein with whole-cell extracts (0.2 mg) prepared from HJC cells constitutively expressing JCV T-Ag utilizing anti-SV40 T-Ag antibody (Ab-2 416). For mapping studies, 0.3 mg of whole-cell extract from HJC cells constitutively expressing JCV T-Ag were incubated with GST, GST-c-Jun, or GST-c-Jun amino- and carboxy-terminal deletion mutants immobilized on glutathione-Sepharose beads. Bound complexes were washed with lysis buffer and analyzed by Western blotting with anti-SV40 T-Ag antibody (Ab-2 416) for the detection of T-Ag. In reciprocal mapping studies, nuclear extracts prepared from U-87MG cells treated with UV were incubated with 2 μg of GST, GST-T-Ag, or GST-T-Ag amino- and carboxy-terminal deletion mutants immobilized on glutathione-Sepharose beads. Bound complexes were analyzed by Western blotting with anti-c-Jun antibody (KM-1) for the detection of c-Jun. All reactions were performed in 400 μl of total reaction volume in lysis buffer overnight at 4°C with continuous rocking. RESULTS AP-1 functionally interacts with large T-Ag. The members of the AP-1 family of transcription factors are involved in regulation of a wide range of cellular processes, including gene activation and repression (52). It has been previously shown that both c-Jun and SV40 large T-Ag are required for inhibition of Po gene promoter expression in secondary Schwann cells (7). Additionally, the induction of apoptosis by SV40 T-Ag correlates with c-Jun overexpression (12), suggesting that both proteins functionally interact with each other. Moreover, our recent findings indicated that an AP-1 family member, c-Jun, binds to its target sequences present within the regulatory region of JCV and regulates transcription from JCV early and late promoters (42). Altogether, these observations suggested the possibility that there would be a functional interaction between these two proteins. To that end, U-87MG cells, which support JCV transcription, were transiently transfected with a reporter construct containing the JCV late promoter alone or together with expression plasmids expressing either c-Jun, c-Fos, or T-Ag transgenes. As shown in Fig. Fig.1A,1A
c-Jun and c-Fos suppress T-Ag-mediated viral DNA replication. T-Ag is a multifunctional phosphoprotein and is required for initiation of JCV DNA replication (15, 32, 33). Transcriptional analysis of the JCV late promoter in the presence of c-Jun and c-Fos and T-Ag by cotransfection experiments showed a functional interaction between these proteins. We further investigated this functional interaction by employing a DpnI-DNA replication assay (10). A replication-competent plasmid containing the JCV origin of DNA replication was transfected alone or in combination with expression plasmids for c-Jun, c-Fos, and T-Ag into U-87MG cells. At 72 h posttransfection, low-molecular-weight DNA was isolated by the Hirt procedure (22) and newly replicated DNA was analyzed by Southern blotting. As shown in Fig. Fig.2,2
T-Ag inhibits c-Jun binding to its target sequences. Our observations from functional assays suggested that c-Jun and T-Ag may associate with each other and influence each other's activity. To investigate the mechanism(s) involved in these observations, we performed electrophoretic mobility band shift assays using both double-stranded 32P end-labeled probe (JCV AP-1 WT, whose sequence is shown in the legend to Fig. Fig.3)3
c-Jun and c-Fos physically associate with T-Ag. Results from both functional and band shift assays indicated that c-Jun and c-Fos may in fact physically interact with JCV large T-Ag. To test this possibility, we performed affinity chromatography (GST pull-down) experiments in which one of the two proteins was bacterially expressed as a GST fusion protein and bound to a glutathione resin, while the other protein was passed over the resin and analyzed for its ability to be specifically retained by the GST fusion protein. GST or GST-T-Ag fusion protein was immobilized on glutathione-Sepharose beads and incubated with nuclear extracts prepared from U-87MG cells either nontreated or treated with UV, which is known to potently induce c-Jun upregulation and phosphorylation (4, 62). Protein complexes bound to GST or GST-T-Ag were washed extensively and analyzed by Western blotting with an anti-c-Jun antibody, which detects both phosphorylated and nonphosphorylated forms of c-Jun on Western blots. As shown in Fig. Fig.4A,4A
A similar GST pull-down assay was performed to demonstrate the association of c-Fos with T-Ag. Whole-cell extracts from hamster glial HJC-15b cells, constitutively expressing T-Ag (37, 59), were incubated with either GST or GST-c-Fos, and after washing, protein complexes retained in the columns were analyzed by Western blotting with an anti-SV40 T-Ag antibody (Ab-2 416). As demonstrated in Fig. Fig.4B,4B We also investigated the protein-protein interaction between c-Jun and T-Ag by using a cell-free system. As shown in Fig. Fig.4C,4C Next, to further examine the association of c-Jun with T-Ag, we performed coimmunoprecipitation experiments. Nuclear extracts prepared from HJC-15b cells were immunoprecipitated either with normal serum (control) or an anti-c-Jun antibody, and immunocomplexes were analyzed by Western blotting for the presence of T-Ag with an anti-T-Ag antibody. Of note, in addition to expressing large T-Ag, HJC-15b cells also express high levels of c-Jun constitutively. As demonstrated in Fig. Fig.4D,4D Mapping of T-Ag interaction domain of c-Jun. In the next series of experiments, we attempted to map the region(s) of c-Jun that are involved in the interaction with T-Ag. A series of deletion mutants of the c-Jun gene was created, and mutant c-Jun proteins fused to GST were incubated with whole-cell lysate from HJC-15b cells. Bound complexes were resolved by SDS-PAGE and analyzed by Western blotting with anti-T-Ag antibody. As shown in Fig. Fig.5A,5A
Localization of c-Jun interaction domain of T-Ag. To identify the protein domain(s) of T-Ag which confers the interaction with c-Jun, a series of T-Ag carboxy-terminal and amino-terminal deletion mutants fused with GST were prepared and incubated with nuclear extracts prepared from U-87MG cells treated with UV. In agreement with the results presented in Fig. Fig.4A,4A
Effect of two c-Jun mutant proteins on T-Ag-mediated gene transcription and replication. To further assess the functional interaction between c-Jun and T-Ag, we examined the ability of mutant c-Jun proteins, which have retained or lost their ability to interact with T-Ag in GST pull-down assays. We chose mutant c-Jun (258-333), which had the ability to strongly interact with T-Ag in in vitro GST pull-down assays, and mutant c-Jun (1-257), which showed no T-Ag binding activity. Transient-transfection assays were performed by utilizing a reporter JCV late CAT construct and expression plasmids for mutants c-Jun (258-333) and c-Jun (1-257). As shown in Fig. Fig.7A,7A
We also examined the effects of these two mutants [c-Jun (1-257) and c-Jun (258-333)] on T-Ag-induced JCV DNA replication. In agreement with the above observations from transfection assays, c-Jun (258-333) strongly inhibited T-Ag-mediated JCV DNA replication (Fig. (Fig.7C).7C DISCUSSION In this report, we examined the molecular mechanism(s) involved in the regulation of JCV gene transcription and replication by the AP-1 family members c-Jun and c-Fos and by the viral protein T-Ag; we showed that both c-Jun and c-Fos interact with T-Ag and negatively regulate T-Ag-mediated viral gene transcription and replication. The members of the AP-1 family of transcription factors are known to regulate transcription from many cellular and viral promoters and are implicated in many important cellular and viral processes, including gene transcription. It has been reported recently that a member of the AP-1 family, c-Jun, specifically interacts with the target DNA binding sequences present within the control region of JCV and regulates transcription from JCV promoters (42). However, it was interesting to observe in this study that c-Jun and c-Fos, individually or in combination, negatively regulate T-Ag-dependent viral gene transcription and replication (Fig. (Fig.11 In addition to performing protein-protein interaction studies to demonstrate physical interaction between c-Jun and T-Ag, we also carried out experiments to map the domain(s) of the interaction of these proteins with each other. The interaction domain of c-Jun with T-Ag maps to the basic DNA binding domain of the protein, which is juxtaposed with the leucine-rich dimerization domain of the protein. This is an important finding in light of our observations from functional assays, and this interaction appears to interfere with the DNA binding and therefore with transcriptional activity of c-Jun. It is known that the DNA binding activity of the AP-1 family of transcription factors is a prerequisite for their transcriptional activity. Results from DNA binding studies (Fig. (Fig.3)3 Transcriptional and replicational regulation of JCV involve a highly organized cascade of events that requires participation of both viral and cellular factors. The combination of cooperative and antagonistic regulatory activities of both viral and cellular transcription factors determines a successful outcome of the viral productive cycle. At the initial stages of viral infection, only host cellular factors are responsible for expression of viral early genes in the absence of the viral large T-Ag. When expressed, JCV large T-Ag in cooperation with cellular factors initiates viral DNA replication and transactivates viral late genes. In the early stages of infection cycle, the immediate-early inducible genes, including the c-Jun and c-Fos genes, which were shown to be induced by viral infection (17), are likely to participate in regulation of JCV early promoter. Consistent with this hypothesis, we have recently demonstrated that the AP-1 family members c-Jun and c-Fos activate transcription from JCV early promoter more strongly than from late promoter (42). In this report, we further investigated the regulatory function of AP-1 family members, in particular c-Jun and c-Fos, through their physical and functional interaction with JCV regulatory protein large T-Ag and presented evidence that both proteins display negative effects on T-Ag-mediated viral gene transcription and replication. The physiological consequence(s) of this negative regulation by AP-1 is currently unknown. However, one can hypothesize that the immediate-early inducible factors, including c-Jun and c-Fos, although displaying positive regulatory roles on the expression of JCV promoters in the absence of T-Ag and at the early phases of infection, may exhibit antagonistic effects on T-Ag-mediated activities during the late phases of infection. This negative regulatory activity by AP-1 may result in a positive effect on viral growth. AP-1 may prolong the survival of infected cells by slowing down both JCV transcription and replication and therefore may positively influence the process of maturation of the infectious viral particles. The study of JCV regulatory processes at the molecular level will shed more light on the molecular mechanisms governing the JCV-host interactions and thereby pave the way to understand the progression of the diseases associated with JCV infections. Acknowledgments The first two authors contributed equally to this work. We thank past and present members of the Center for Neurovirology and Cancer Biology for their insightful discussion and sharing of ideas and reagents. We also thank Cynthia Schriver for editorial assistance. This work was made possible by grants awarded by NIH to K.K., S.A., and M.S. REFERENCES 1. Amemiya, K., R. Traub, L. Durham, and E. O. Major. 1992. Adjacent nuclear factor-1 and activator protein binding sites in the enhancer of the neurotropic JC virus. A common characteristic of many brain-specific genes. J. Biol. Chem. 267:14204-14211. [PubMed] 2. Amemiya, K., R. Traub, L. Durham, and E. O. Major. 1989. Interaction of a nuclear factor-1-like protein with the regulatory region of the human polyomavirus JC virus. J. Biol. Chem. 264:7025-7032. [PubMed] 3. Angel, P., M. Imagawa, R. Chiu, B. Stein, R. J. Imbra, H. J. Rahmsdorf, C. Jonat, P. Herrlich, and M. Karin. 1987. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 49:729-739. [PubMed] 4. Angel, P., and M. Karin. 1991. The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim. Biophys. Acta 1072:129-157. [PubMed] 5. Angel, P., and M. Karin. 1992. Specific members of the Jun protein family regulate collagenase expression in response to various extracellular stimuli. Matrix Suppl. 1:156-164. [PubMed] 6. Berger, J. R., and M. Concha. 1995. Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare. J. Neurovirol. 1:5-18. [PubMed] 7. Bharucha, V. D., K. W. C. Peden, and G. I. Tennekoon. 1994. SV40 large T antigen with c-Jun down regulates myelin Po gene expression: a mechanism for papovaviral T antigen-mediated demyelination. Neuron 12:627-637. [PubMed] 8. Bossy-Wetzel, E., L. Bakiri, and M. Yaniv. 1997. Induction of apoptosis by the transcription factor c-Jun. EMBO J. 16:1695-1709. [PubMed] 9. Brenner, D. A., M. O'Hara, P. Angel, M. Chojkier, and M. Karin. 1989. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature 337:661-663. [PubMed] 10. Chang, C. F., G. L. Gallia, V. Muralidharan, N. N. Chen, P. Zoltick, E. Johnson, and K. Khalili. 1996. Evidence that replication of human neurotropic JC virus DNA in glial cells is regulated by the sequence-specific single-stranded DNA-binding protein Pur alpha. J. Virol. 70:4150-4156. [PubMed] 11. Chen, N. N., and K. Khalili. 1995. Transcriptional regulation of human JC polyomavirus promoters by cellular proteins YB-1 and Pur alpha in glial cells. J. Virol. 69:5843-5848. [PubMed] 12. Chen, S. L., Y. P. Tsoa, Y. L. Chen, S. J. Huang, J. L. Chang, and S. F. Wu. 1998. The induction of apoptosis by SV40 T antigen correlates with c-Jun overexpression. Virology 244:521-529. [PubMed] 13. Devary, Y., R. A. Gottlieb, L. F. Lau, and M. Karin. 1991. Rapid and preferential activation of the c-jun gene during the mammalian UV response. Mol. Cell. Biol. 11:2804-2811. [PubMed] 14. Frisque, R. J. 2001. Structure and function of JC virus T' proteins. J. Neurovirol. 7:293-297. [PubMed] 15. Frisque, R. J., and F. A. White. 1992. The molecular biology of JC virus, causative agent of progressive multifocal leukoencephalopathy. Humana Press Inc., Totowa, N.J. 16. Gallia, G. L., M. Safak, and K. Khalili. 1998. Interaction of the single-stranded DNA-binding protein Puralpha with the human polyomavirus JC virus early protein T-antigen. J. Biol. Chem. 273:32662-32669. [PubMed] 17. Glenn, G. M., and W. Echart. 1990. Transcriptional regulation of early-response genes during polyomavirus infection. J. Virol. 64:2193-2201. [PubMed] 18. Goldgaber, D., H. W. Harris, T. Hla, T. Maciag, R. J. Donnelly, J. S. Jacobsen, M. P. Vitek, and D. C. Gajdusek. 1989. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA 86:7606-7610. [PubMed] 19. Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-467. [PubMed] 20. Henson, J., J. Saffer, and H. Furneaux. 1992. The transcription factor Sp1 binds to the JC virus promoter and is selectively expressed in glial cells in human brain. Ann. Neurol. 32:72-77. [PubMed] 21. Herrlich, P., H. Ponta, and H. J. Rahmsdorf. 1992. DNA damage-induced gene expression: signal transduction and relation to growth factor signaling. Rev. Physiol. Biochem. Pharmacol. 119:187-223. [PubMed] 22. Hirt, B. J. 1976. Selective extraction of polyoma DNA from infected mouse cell culture. J. Mol. Biol. 26:365-369. 23. Johnson, R. S., B. van Lingen, V. E. Papaioannou, and B. M. Spiegelman. 1993. A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture. Genes Dev. 7:1309-1317. [PubMed] 24. Kerr, D., C. F. Chang, N. Chen, G. Gallia, G. Raj, B. Schwartz, and K. Khalili. 1994. Transcription of a human neurotropic virus promoter in glial cells: effect of YB-1 on expression of the JC virus late gene. J. Virol. 68:7637-7643. [PubMed] 25. Khalili, K., L. Feigenbaum, and G. Khoury. 1987. Evidence for a shift in 5′-termini of early viral RNA during the lytic cycle of JC virus. Virology 158:469-472. [PubMed] 26. Krynska, B., L. Del Valle, S. Croul, J. Gordon, C. D. Katsetos, M. Carbone, A. Giordano, and K. Khalili. 1999. Detection of human neurotropic JC virus DNA sequence and expression of the viral oncogenic protein in pediatric medulloblastomas. Proc. Natl. Acad. Sci. USA 96:11519-11524. [PubMed] 27. Krynska, B., J. Otte, R. Franks, K. Khalili, and S. Croul. 1999. Human ubiquitous JCV(CY) T-antigen gene induces brain tumors in experimental animals. Oncogene 18:39-46. [PubMed] 28. Laghi, L., A. E. Randolph, D. P. Chauhan, G. Marra, E. O. Major, J. V. Neel, and C. R. Boland. 1999. JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. Proc. Natl. Acad. Sci. USA 96:7484-7489. [PubMed] 29. Lashgari, M. S., H. Tada, S. Amini, and K. Khalili. 1989. Regulation of JCVL promoter function: transactivation of JCVL promoter by JCV and SV40 early proteins. Virology 170:292-295. [PubMed] 30. Le-Niculescu, H., E. Bonfoco, Y. Kasuya, F. X. Claret, D. R. Green, and M. Karin. 1999. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell. Biol. 19:751-763. [PubMed] 31. Liu, C. K., A. P. Hope, and W. J. Atwood. 1998. The human polyomavirus, JCV, does not share receptor specificity with SV40 on human glial cells. J. Neurovirol. 4:49-58. [PubMed] 32. Lynch, K. J., and R. J. Frisque. 1991. Factors contributing to the restricted DNA replicating activity of JC virus. Virology 180:306-317. [PubMed] 33. Lynch, K. J., and R. J. Frisque. 1990. Identification of critical elements within the JC virus DNA replication origin. J. Virol. 64:5812-5822. [PubMed] 34. Lynch, K. J., S. Haggerty, and R. J. Frisque. 1994. DNA replication of chimeric JC virus-simian virus 40 genomes. Virology 204:819-822. [PubMed] 35. Monaco, M. C., B. F. Sabath, L. C. Durham, and E. O. Major. 2001. JC virus multiplication in human hematopoietic progenitor cells requires the NF-1 class D transcription factor. J. Virol. 75:9687-9695. [PubMed] 36. Pho, M. T., A. Ashok, and W. J. Atwood. 2000. JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J. Virol. 74:2288-2292. [PubMed] 37. Raj, G. V., J. Gordon, T. J. Logan, D. J. Hall, A. Deluca, A. Giordano, and K. Khalili. 1995. Characterization of glioma cells derived from polyomavirus-induced brain tumors in hamsters. Int. J. Oncol. 7:801-808. 38. Raj, G. V., and K. Khalili. 1994. Identification and characterization of a novel GGA/C-binding protein, GBP-i, that is rapidly inducible by cytokines. Mol. Cell. Biol. 14:7770-7781. [PubMed] 39. Ranganathan, P. N., and K. Khalili. 1993. The transcriptional enhancer element, kappa B, regulates promoter activity of the human neurotropic virus, JCV, in cells derived from the CNS. Nucleic Acids Res. 21:1959-1964. [PubMed] 40. Rencic, A., J. Gordon, J. Otte, M. Curtis, A. Kovatich, P. Zoltick, K. Khalili, and D. Andrews. 1996. Detection of JC virus DNA sequence and expression of the viral oncoprotein, tumor antigen, in brain of immunocompetent patient with oligoastrocytoma. Proc. Natl. Acad. Sci. USA 93:7352-7357. [PubMed] 41. Renner, K., H. Leger, and M. Wegner. 1994. The POU domain protein Tst-1 and papovaviral large tumor antigen function synergistically to stimulate glia-specific gene expression of JC virus. Proc. Natl. Acad. Sci. USA 91:6433-6437. [PubMed] 42. Sadowska, B., R. Barucco, K. Khalili, and M. Safak. 2003. Regulation of human polyomavirus JC virus gene transcription by AP-1 in glial cells. J. Virol. 77:665-672. [PubMed] 43. Safak, M., R. Barrucco, A. Darbinyan, Y. Okada, K. Nagashima, and K. Khalili. 2001. Interaction of JC virus agno protein with T antigen modulates transcription and replication of the viral genome in glial cells. J. Virol. 75:1476-1486. [PubMed] 44. Safak, M., G. L. Gallia, S. A. Ansari, and K. Khalili. 1999. Physical and functional interaction between the Y-box binding protein YB-1 and human polyomavirus JC virus large T antigen. J. Virol. 73:10146-10157. [PubMed] 45. Safak, M., G. L. Gallia, and K. Khalili. 1999. A 23-bp sequence element from human neurotropic JC virus is responsive to NF-kappa B subunits. Virology 262:178-189. [PubMed] 46. Safak, M., G. L. Gallia, and K. Khalili. 1999. Reciprocal interaction between two cellular proteins, Puralpha and YB-1, modulates transcriptional activity of JCVCY in glial cells. Mol. Cell. Biol. 19:2712-2723. [PubMed] 47. Safak, M., and K. Khalili. 2001. Physical and functional interaction between viral and cellular proteins modulate JCV gene transcription. J. Neurovirol. 7:288-292. [PubMed] 48. Safak, M., B. Sadowska, R. Barrucco, and K. Khalili. 2002. Functional interaction between JC virus late regulatory agnoprotein and cellular Y-box binding transcription factor, YB-1. J. Virol. 76:3828-3838. [PubMed] 49. Schreiber, E., P. Matthias, M. M. Muller, and W. Schaffner. 1989. Rapid detection of octamer binding proteins with “mini-extracts”, prepared from a small number of cells. Nucleic Acids Res. 17:6419.. [PubMed] 50. Shaulian, E., and M. Karin. 2001. AP-1 in cell proliferation and survival. Oncogene 20:2390-2400. [PubMed] 51. Shaulian, E., M. Schreiber, F. Piu, M. Beeche, E. F. Wagner, and M. Karin. 2000. The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. Cell 103:897-907. [PubMed] 52. Shaulian, E., and M. Karin. 2002. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4:E131-E136. [PubMed] 53. Small, J. A., G. Khoury, G. Jay, P. M. Howley, and G. A. Scangos. 1986. Early regions of JC virus and BK virus induce distinct and tissue-specific tumors in transgenic mice. Proc. Natl. Acad. Sci. USA 83:8288-8292. [PubMed] 54. Tavis, J. E., and R. J. Frisque. 1991. Altered DNA binding and replication activities of JC virus T-antigen mutants. Virology 183:239-250. [PubMed] 55. Trowbridge, P. W., and R. J. Frisque.1995. Identification of three new JC virus proteins generated by alternative splicing of the early viral mRNA. J. Neurovirol. 1:195-206. [PubMed] 56. van Straaten, F., R. Muller, T. Curran, C. Van Beveren, and I. M. Verma. 1983. Complete nucleotide sequence of a human c-onc gene: deduced amino acid sequence of the human c-fos protein. Proc. Natl. Acad. Sci. USA 80:3183-3187. [PubMed] 57. Varakis, J., G. M. ZuRhein, B. L. Padgett, and D. L. Walker. 1978. Induction of peripheral neuroblastomas in Syrian hamsters after injection as neonates with JC virus, a human polyoma virus. Cancer Res. 38:1718-1722. [PubMed] 58. Vogt, P. 2001. Jun, the oncogene. Oncogene 20:2365-2377. [PubMed] 59. Walker, D. L., B. L. Padgett, G. M. ZuRhein, A. E. Albert, and R. F. Marsh. 1973. Human papovavirus (JC): induction of brain tumors in hamsters. Science 181:674-676. [PubMed] 60. Wegner, M., D. W. Drolet, and M. G. Rosenfeld. 1993. Regulation of JC virus by the POU-domain transcription factor Tst-1: implications for progressive multifocal leukoencephalopathy. Proc. Natl. Acad. Sci. USA 90:4743-4747. [PubMed] 61. Wei, G., C. K. Liu, and W. J. Atwood. 2000. JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes. J. Neurovirol. 6:127-136. [PubMed] 62. Wisdom, R. 1992. AP-1: one switch for many signals. Exp. Cell Res. 253:180-185. 63. Zullo, J., C. D. Stiles, and R. L. Garcea. 1987. Regulation of c-myc and c-fos mRNA levels by polyomavirus: distinct roles for the capsid protein VP1 and the viral early proteins. Proc. Natl. Acad. Sci. USA 84:1210-1214. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Nat Cell Biol. 2002 May; 4(5):E131-6.
[Nat Cell Biol. 2002]Genes Dev. 1993 Jul; 7(7B):1309-17.
[Genes Dev. 1993]Biochim Biophys Acta. 1991 Dec 10; 1072(2-3):129-57.
[Biochim Biophys Acta. 1991]Oncogene. 2001 Apr 30; 20(19):2390-400.
[Oncogene. 2001]Cell. 1987 Jun 19; 49(6):729-39.
[Cell. 1987]Biochim Biophys Acta. 1991 Dec 10; 1072(2-3):129-57.
[Biochim Biophys Acta. 1991]Nature. 1989 Feb 16; 337(6208):661-3.
[Nature. 1989]Mol Cell Biol. 1991 May; 11(5):2804-11.
[Mol Cell Biol. 1991]J Virol. 1990 May; 64(5):2193-201.
[J Virol. 1990]Proc Natl Acad Sci U S A. 1989 Oct; 86(19):7606-10.
[Proc Natl Acad Sci U S A. 1989]J Neurovirol. 1995 Mar; 1(1):5-18.
[J Neurovirol. 1995]J Neurovirol. 1998 Feb; 4(1):49-58.
[J Neurovirol. 1998]J Virol. 2000 Mar; 74(5):2288-92.
[J Virol. 2000]J Neurovirol. 2000 Apr; 6(2):127-36.
[J Neurovirol. 2000]Nucleic Acids Res. 1993 Apr 25; 21(8):1959-64.
[Nucleic Acids Res. 1993]Neuron. 1994 Mar; 12(3):627-37.
[Neuron. 1994]Virology. 1998 May 10; 244(2):521-9.
[Virology. 1998]J Biol Chem. 1989 Apr 25; 264(12):7025-32.
[J Biol Chem. 1989]J Virol. 2003 Jan; 77(1):665-72.
[J Virol. 2003]Science. 1973 Aug 17; 181(100):674-6.
[Science. 1973]J Virol. 1995 Sep; 69(9):5843-8.
[J Virol. 1995]J Virol. 1999 Dec; 73(12):10146-57.
[J Virol. 1999]J Virol. 1996 Jun; 70(6):4150-6.
[J Virol. 1996]Virology. 1973 Apr; 52(2):456-67.
[Virology. 1973]J Neurovirol. 2001 Aug; 7(4):288-92.
[J Neurovirol. 2001]Nucleic Acids Res. 1989 Aug 11; 17(15):6419.
[Nucleic Acids Res. 1989]Mol Cell Biol. 1999 Apr; 19(4):2712-23.
[Mol Cell Biol. 1999]J Virol. 2002 Apr; 76(8):3828-38.
[J Virol. 2002]Nat Cell Biol. 2002 May; 4(5):E131-6.
[Nat Cell Biol. 2002]Neuron. 1994 Mar; 12(3):627-37.
[Neuron. 1994]Virology. 1998 May 10; 244(2):521-9.
[Virology. 1998]J Virol. 2003 Jan; 77(1):665-72.
[J Virol. 2003]Virology. 1989 May; 170(1):292-5.
[Virology. 1989]Virology. 1991 Jan; 180(1):306-17.
[Virology. 1991]J Virol. 1990 Dec; 64(12):5812-22.
[J Virol. 1990]J Virol. 1996 Jun; 70(6):4150-6.
[J Virol. 1996]Biochim Biophys Acta. 1991 Dec 10; 1072(2-3):129-57.
[Biochim Biophys Acta. 1991]Science. 1973 Aug 17; 181(100):674-6.
[Science. 1973]J Biol Chem. 1998 Dec 4; 273(49):32662-9.
[J Biol Chem. 1998]J Virol. 1999 Dec; 73(12):10146-57.
[J Virol. 1999]J Virol. 2003 Jan; 77(1):665-72.
[J Virol. 2003]Neuron. 1994 Mar; 12(3):627-37.
[Neuron. 1994]Matrix Suppl. 1992; 1():156-64.
[Matrix Suppl. 1992]J Virol. 1990 May; 64(5):2193-201.
[J Virol. 1990]J Virol. 2003 Jan; 77(1):665-72.
[J Virol. 2003]